Solve has selected Simmaron Research as the recipient of our latest ME/CFS Catalyst Award. The funds will be used to accelerate a low-dose rapamycin trial for ME/CFS, Long COVID, and other infection-associated chronic conditions (IACCs). The study advances an FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid, repurposing rapamycin to reduce fatigue, orthostatic intolerance, post-exertional malaise, and sleep issues for a subset of people with ME/CFS.
